Publication:
Effectiveness of a Meningococcal Group B Vaccine (4CMenB) in Children.

dc.contributor.authorCastilla, Jesús
dc.contributor.authorGarcía Cenoz, Manuel
dc.contributor.authorAbad, Raquel
dc.contributor.authorSánchez-Cambronero, Laura
dc.contributor.authorLorusso, Nicola
dc.contributor.authorIzquierdo, Conchita
dc.contributor.authorCañellas Llabrés, Soledad
dc.contributor.authorRoig, Javier
dc.contributor.authorMalvar, Alberto
dc.contributor.authorGonzález Carril, Fernando
dc.contributor.authorBoone, An L.D.
dc.contributor.authorPérez Martín, Jaime
dc.contributor.authorRodríguez Recio, M. Jesús
dc.contributor.authorGalmés, Antònia
dc.contributor.authorCaballero, Arturo
dc.contributor.authorGarcía Rojas, Amós
dc.contributor.authorJuanas, Felipe
dc.contributor.authorNieto, Mercedes
dc.contributor.authorViloria Raymundo, Luis J.
dc.contributor.authorMartínez Ochoa, Eva
dc.contributor.authorRivas, Ana I.
dc.contributor.authorCastrillejo, Daniel
dc.contributor.authorMoreno Pérez, David
dc.contributor.authorMartínez, Ana
dc.contributor.authorBorràs, Eva
dc.contributor.authorSánchez Gómez, Amaya
dc.contributor.authorPastor, Eliseo
dc.contributor.authorNartallo, Victoria
dc.contributor.authorArteagoitia, José M.
dc.contributor.authorÁlvarez-Fernández, Blanca
dc.contributor.authorGarcía Pina, Rocío
dc.contributor.authorFernández Arribas, Socorro
dc.contributor.authorVanrell, Joana
dc.contributor.authorGarcía Hernández, Sara
dc.contributor.authorMendoza, Rita M.
dc.contributor.authorMéndez, Manuel
dc.contributor.authorLópez-Tercero, M. Mar
dc.contributor.authorFernández-Rodríguez, Ángela
dc.contributor.authorBlanco, Ángela
dc.contributor.authorCarrillo de Albornoz, F. Javier
dc.contributor.authorRuiz Olivares, José
dc.contributor.authorRuiz-Montero, Rafael
dc.contributor.authorLimia, Aurora
dc.contributor.authorNavarro-Alonso, José A.
dc.contributor.authorVazquez-Moreno, Julio Alberto
dc.contributor.authorBarricarte, Aurelio
dc.date.accessioned2026-11-05T11:49:25Z
dc.date.available2026-11-05T11:49:25Z
dc.date.issued2023-02-02
dc.description.abstractBackground: In September 2015, the four-component, protein-based meningococcal serogroup B vaccine (4CMenB; Bexsero) became available for private purchase in Spain. Methods: We conducted a nationwide matched case-control study to assess the effectiveness of 4CMenB in preventing invasive meningococcal disease in children. The study included all laboratory-confirmed cases of invasive meningococcal disease in children younger than 60 months of age between October 5, 2015, and October 6, 2019, in Spain. Each case patient was matched with four controls according to date of birth and province. 4CMenB vaccination status of the case patients and controls was compared with the use of multivariate conditional logistic regression. Results: We compared 306 case patients (243 [79.4%] with serogroup B disease) with 1224 controls. A total of 35 case patients (11.4%) and 298 controls (24.3%) had received at least one dose of 4CMenB. The effectiveness of complete vaccination with 4CMenB (defined as receipt of at least 2 doses, administered in accordance with the manufacturer's recommendations) was 76% (95% confidence interval [CI], 57 to 87) against invasive meningococcal disease caused by any serogroup, and partial vaccination was 54% (95% CI, 18 to 74) effective. Complete vaccination resulted in an effectiveness of 71% (95% CI, 45 to 85) against meningococcal serogroup B disease. Vaccine effectiveness with at least one dose of 4CMenB was 64% (95% CI, 41 to 78) against serogroup B disease and 82% (95% CI, 21 to 96) against non-serogroup B disease. With the use of the genetic Meningococcal Antigen Typing System, serogroup B strains that were expected to be covered by 4CMenB were detected in 44 case patients, none of whom had been vaccinated. Conclusions: Complete vaccination with 4CMenB was found to be effective in preventing invasive disease by serogroup B and non-serogroup B meningococci in children younger than 5 years of age.
dc.description.peerreviewedSí
dc.format.number5
dc.format.page427-438
dc.format.volume388
dc.identifier.citationCastilla J, García Cenoz M, Abad R, Sánchez-Cambronero L, Lorusso N, Izquierdo C, Cañellas Llabrés S, Roig J, Malvar A, González Carril F, Boone ALD, Pérez Martín J, Rodríguez Recio MJ, Galmés A, Caballero A, García Rojas A, Juanas F, Nieto M, Viloria Raymundo LJ, Martínez Ochoa E, Rivas AI, Castrillejo D, Moreno Pérez D, Martínez A, Borràs E, Sánchez Gómez A, Pastor E, Nartallo V, Arteagoitia JM, Álvarez-Fernández B, García Pina R, Fernández Arribas S, Vanrell J, García Hernández S, Mendoza RM, Méndez M, López-Tercero MM, Fernández-Rodríguez Á, Blanco Á, Carrillo de Albornoz FJ, Ruiz Olivares J, Ruiz-Montero R, Limia A, Navarro-Alonso JA, Vázquez JA, Barricarte A. Effectiveness of a Meningococcal Group B Vaccine (4CMenB) in Children. N Engl J Med. 2023 Feb 2;388(5):427-438. doi: 10.1056/NEJMoa2206433. PMID: 36724329.
dc.identifier.doi10.1056/nejmoa2206433
dc.identifier.issn0028-4793
dc.identifier.issn1533-4406
dc.identifier.journalThe New England Journal of Medicine
dc.identifier.pubmedID36724329
dc.identifier.urihttps://hdl.handle.net/20.500.12105/27807
dc.issue.number5
dc.journal.titleNew England Journal of Medicine
dc.language.isoeng
dc.publisherMassachusetts Medical Society
dc.relation.publisherversionhttps://doi.org/10.1056/NEJMoa2206433
dc.repisalud.centroISCIII::Centro Nacional de Microbiología (CNM)
dc.repisalud.institucionISCIII
dc.rights.accessRightsopen access
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject.meshCase-Control Studies
dc.subject.meshChild
dc.subject.meshHumans
dc.subject.meshInfant
dc.subject.meshMeningococcal Infections
dc.subject.meshNeisseria meningitidis
dc.subject.meshNeisseria meningitidis, Serogroup B
dc.subject.meshSpain
dc.titleEffectiveness of a Meningococcal Group B Vaccine (4CMenB) in Children.
dc.typeresearch article
dc.type.hasVersionAM
dc.volume.number388
dspace.entity.typePublication
relation.isAuthorOfPublicationae1b542d-e7ab-49ee-86bd-700209d166c1
relation.isAuthorOfPublicationc5b6f138-e581-4216-b2ab-ee813c9e410d
relation.isAuthorOfPublication.latestForDiscoveryae1b542d-e7ab-49ee-86bd-700209d166c1
relation.isPublisherOfPublication42b664e1-57a8-4eea-9554-f5cff091b3f6
relation.isPublisherOfPublication.latestForDiscovery42b664e1-57a8-4eea-9554-f5cff091b3f6

Files

Original bundle

Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
EffectivenessMeningococcalGroupBVaccine_2023.pdf
Size:
558.89 KB
Format:
Adobe Portable Document Format
Loading...
Thumbnail Image
Name:
Supplementary_EffectivenessMeningococcalGroupBVaccine_2023.pdf
Size:
4.06 MB
Format:
Adobe Portable Document Format